Autoimmune Diseases of the Nervous System
Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).
Subtype terms (9)
More specific conditions that are subtypes of Autoimmune Diseases of the Nervous System in the MeSH hierarchy.
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis
7 drugs (5 approved, 2 experimental)
- Cogan Syndrome
3 drugs approved
- Demyelinating Autoimmune Diseases, CNS
10 drugs (8 approved, 2 experimental)
- Myasthenia Gravis
93 drugs (51 approved, 42 experimental)
- Nervous System Autoimmune Disease, Experimental
- Polyradiculoneuropathy
25 drugs (17 approved, 8 experimental)
- Stiff-Person Syndrome
18 drugs (15 approved, 3 experimental)
- Uveomeningoencephalitic Syndrome
3 drugs approved
- Vasculitis, Central Nervous System
10 drugs (6 approved, 4 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (2)
Phase 2 trials (12)
Phase 1 trials (9)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 2 Indications (14)
- Gilead Sciences
- Eli Lilly
- Baxalta
- Fundación Pública Andaluza
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Human Genome Research Institute (NHGRI)
- University of Pennsylvania
- Emory University
- University of Washington
- University of Seville
- Opexa Therapeutics
- University of Paris
- Emerson Resources
Organization Involved with Phase 1 Indications (2)